CN109520979B - A kind of detection method of cholesterol in serum - Google Patents
A kind of detection method of cholesterol in serum Download PDFInfo
- Publication number
- CN109520979B CN109520979B CN201811304853.9A CN201811304853A CN109520979B CN 109520979 B CN109520979 B CN 109520979B CN 201811304853 A CN201811304853 A CN 201811304853A CN 109520979 B CN109520979 B CN 109520979B
- Authority
- CN
- China
- Prior art keywords
- solution
- cholesterol
- cqds
- fluorescence
- aunps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 130
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 63
- 210000002966 serum Anatomy 0.000 title claims abstract description 20
- 238000001514 detection method Methods 0.000 title claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 29
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000011550 stock solution Substances 0.000 claims abstract description 4
- 238000011084 recovery Methods 0.000 claims description 10
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 9
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 9
- 239000012086 standard solution Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- 230000005284 excitation Effects 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000000295 emission spectrum Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 5
- 238000004847 absorption spectroscopy Methods 0.000 abstract description 4
- 238000004737 colorimetric analysis Methods 0.000 abstract description 4
- 238000002848 electrochemical method Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 47
- 229920000858 Cyclodextrin Polymers 0.000 description 35
- 229960004853 betadex Drugs 0.000 description 35
- 239000001116 FEMA 4028 Substances 0.000 description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229910004042 HAuCl4 Inorganic materials 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- -1 β -CD @ AuNPs Chemical compound 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明公开了一种血清中胆固醇的检测方法，包括如下步骤：(1)将β‑CD@AuNPs、CQDs和适量以无水乙醇为溶剂制备的胆固醇储备液混合后，配制不同浓度的胆固醇标准溶液，于特定荧光条件下绘制工作曲线；(2)获得待测血清，进行检测；(3)将步骤(2)的检测结果代入工作曲线中，得到待测血清中的胆固醇浓度。本发明不仅能够克服色谱法，电化学法，比色法，等离子体吸收光谱法等技术的缺陷，且具检测线性范围广、灵敏度较高、选择性好等优势。
The invention discloses a method for detecting cholesterol in serum, comprising the following steps: (1) after mixing β-CD@AuNPs, CQDs and an appropriate amount of cholesterol stock solution prepared with absolute ethanol as a solvent, preparing cholesterol standards of different concentrations solution, and draw a working curve under specific fluorescence conditions; (2) obtain the serum to be tested and detect; (3) substitute the detection result of step (2) into the working curve to obtain the cholesterol concentration in the serum to be tested. The invention can not only overcome the defects of chromatography, electrochemical method, colorimetry, plasma absorption spectrometry and the like, but also has the advantages of wide detection linear range, high sensitivity, good selectivity and the like.
Description
Technical Field
The invention belongs to the technical field of biological small molecule analysis and detection, and particularly relates to a method for detecting cholesterol in serum.
Background
Cholesterol, which was first discovered from gallstones, is widely present in animals, is a basic structural component of all animal cell membranes, plays an important role in maintaining the structural integrity and fluidity of membranes, and requires cholesterol as a raw material for the synthesis of bile acids, vitamin D and hormones. The normal level of total cholesterol in the serum of healthy persons is generally lower than 5.2 mmol.L-1. Excessive blood cholesterol levels, known as hypercholesterolemia, significantly increase the risk of vascular disease such as coronary heart disease, hypertension and atherosclerosis. On the other hand, the lack of cholesterol is considered to be associated with the occurrence of diseases such as depression, cancer and cerebral hemorrhage. With the improvement of living standard, diseases such as coronary heart disease, diabetes and hypertension caused by abnormal cholesterol are in a growing trend, and cholesterol is classified as a class 3 carcinogen by the international cancer research organization of the world health organization. Therefore, development of a method for detecting serum cholesterolThe method of sterol content is of paramount importance.
Various analytical methods have been developed for the detection of cholesterol content, such as chromatography and electrochemical binding, chromatography, electrochemical methods, colorimetric methods, plasma absorption spectroscopy, and the like. However, most methods require a cumbersome experimental process and are expensive; or rely on the high selectivity catalytic reaction of cholesterol oxidase to carry out cholesterol determination, but this method is unstable and expensive due to the volatile activity of the enzyme; or hazardous chemicals are used in the process. Therefore, it is necessary to develop a method with high selectivity, low cost and environmental protection to further improve the defects of the current method.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a method for detecting cholesterol in serum.
The technical scheme of the invention is as follows:
a method for detecting cholesterol in serum comprises the following steps:
(1) mixing beta-CD @ AuNPs, CQDs and a proper amount of cholesterol stock solution prepared by taking absolute ethyl alcohol as a solvent, and preparing cholesterol standard solutions with different concentrations; fixing the fluorescence excitation wavelength at 390nm, recording the fluorescence emission spectra of cholesterol standard solutions with different concentrations, and taking the intensity of the fluorescence emission peak Em 528nm as the quantitative basis and the fluorescence recovery efficiency (F-F)0)/F0Linear fitting of different cholesterol concentrations, determination of detection limits, F0F is the intensity of the fluorescence emission peak Em at 528nm corresponding to the concentration of different cholesterol standard solutions; when the concentration of cholesterol is 10-210 mu mol.L-1Fluorescence recovery efficiency (F-F)0)/F0Shows good linear relation with the concentration of cholesterol, and obtains a linear working curve y which is 0.0052x-0.0139, R2＝0.996，y＝(F-F0)/F0X is cholesterol concentration; the beta-CD @ AuNPs are gold chloride acid (HAuCl)4) The solution is taken as a precursor, beta-cyclodextrin (beta-CD) is taken as a reducing agent and a stabilizing agent, the solution is prepared by heating and refluxing in one step,the CQDs are synthesized by taking cetylpyridinium chloride (CPC) solution as a precursor through an ultrasonic one-step method;
(2) preserving fresh blood at room temperature overnight, and centrifuging light yellow supernatant every other day to obtain serum; adding 0-160 mu mol.L into the serum-1The cholesterol standard solution is subjected to fluorescence measurement according to the parameters in the step (1), and the measurement is repeated at least three times to obtain the intensity of a corresponding fluorescence emission peak Em at 528 nm;
(3) the intensity of the fluorescence emission peak Em 528nm obtained in step (3) was substituted into the above linear working curve to obtain the concentration of cholesterol in serum.
In a preferred embodiment of the present invention, the β -CD @ AuNPs are prepared by the following steps: ultrapure water is added into the reaction vessel in sequence, and 0.1 mol.L-1And PBS buffer of pH 7.0, 0.01mol. L-1HAuCl of4Solution and 0.01mol.L-1Stirring the beta-CD aqueous solution uniformly, transferring the solution into an oil bath kettle, strongly stirring and refluxing the solution at 100 ℃ for 60min to change the color of the solution from light yellow to light red to wine red, naturally cooling the solution, filtering the solution through a 0.45 mu m filter membrane, and storing the solution at 4 ℃.
More preferably, the ultrapure water, PBS buffer solution and HAuCl are used4The volume ratio of the solution to the beta-CD aqueous solution is 35: 5: 1: 10.
In a preferred embodiment of the present invention, the CQDs are prepared by a method comprising: to 15 mmol. L-1Adding 2.0 mol. L to the CPC solution-1After the ultrasonic treatment is carried out for 30min, the pH value of the solution is adjusted to 7.0 by concentrated hydrochloric acid, the reaction is terminated, and the CQDs solid is obtained by freeze drying after being dialyzed for 24h by a dialysis bag, and is dissolved in water again according to the concentration required by the experiment and stored at 4 ℃; the solution changed color from colorless to light yellow and finally to brown-yellow during sonication.
Further preferably, the volume ratio of the CPC solution to the NaOH solution is 100: 9.
In a preferred embodiment of the present invention, the average particle size of the β -CD @ AuNPs is 24 to 26nm, respectively.
In a preferred embodiment of the present invention, the CQDs have average particle diameters of 2.8 to 3.2nm, respectively.
The invention has the beneficial effects that: the invention not only can overcome the defects of technologies such as chromatography, electrochemistry, colorimetry, plasma absorption spectrometry and the like, but also has the advantages of wide detection linear range, higher sensitivity, good selectivity and the like.
Drawings
FIG. 1 is a Transmission Electron Microscope (TEM) image of (a) β -CD @ AuNPs in example 1 of the present invention; (b) high Resolution Transmission Electron Microscopy (HRTEM) images of single β -CD @ AuNPs; (c) a particle size distribution histogram of beta-CD @ AuNPs; (d) TEM image of CQDs and (d) histogram of particle size distribution.
FIG. 2 is a fluorescence excitation spectrum (Ex. about. 390nm) and an emission spectrum (Em. about. 528nm) of CQDs in example 1 of the present invention, and an ultraviolet-visible absorption spectrum (Abs) of β -CD @ AuNPs, in which 1 to 4 and 5 to 8 are CQDs, β -CD @ AuNPs, CQDs/β -CD @ AuNPs/cholesterol under sunlight and 365nm ultraviolet light, respectively; (b) CQDs, CQDs/beta-CD @ AuNPs and CQDs/beta-CD @ AuNPs are added with 60 mu mol.L-1Fluorescence spectrum of cholesterol.
FIG. 3 is a graph showing fluorescence emission spectra of CQDs in example 1 of the present invention after adding various concentrations of β -CD @ AuNPs; (b) f0Curve relating/F to concentration of beta-CD @ AuNPs (F)0The fluorescence emission peak intensity of CQDs when no beta-CD @ AuNPs are added, F is the fluorescence emission peak intensity after different concentrations of beta-CD @ AuNPs are added, and Ex is 390nm and Em is 528 nm); (c) the curve of the change of fluorescence intensity with time before and after adding beta-CD @ AuNPs (2mL) into CQDs; (d) cholesterol (60. mu. mol. L) is added into CQDs/beta-CD @ AuNPs-1) Plot of the intensity of the post-fluorescence versus time.
FIG. 4 is a graph showing the fluorescence selective responses of (a) various substances to CQDs/β -CD @ AuNPs in example 1 of the present invention; (b) and (3) fitting a fluorescence standard curve of CQDs/beta-CD @ AuNPs to cholesterol concentration and corresponding colorimetric images.
Detailed Description
The technical solution of the present invention is further illustrated and described by the following detailed description.
Example 1:
1. preparation of beta-CD @ AuNPs and CQDs
The beta-CD @ AuNPs are prepared from chloroauric acid (HAuCl)4) The solution is used as a precursor, beta-cyclodextrin (beta-CD) is used as a reducing agent and a stabilizing agent, and the gold nanoparticles (beta-CD @ AuNPs) modified by the beta-cyclodextrin are prepared in one step by heating and refluxing. The method comprises the following specific steps: 35mL of ultrapure water and 5mL of PBS buffer (0.1 mol. L) were added to the flask-1pH 7.0), 1mL of HAuCl4Solution (0.01 mol. L)-1) And 10mL of an aqueous solution of beta-CD (0.01 mol. L)-1) Stirring uniformly, transferring into oil bath, strongly stirring and refluxing at 100 deg.C for 60min to change the color of the solution from light yellow to light red and finally to wine red. After the solution was cooled naturally, it was filtered through a 0.45 μm filter and stored at 4 ℃ (PBS buffer solution (0.1 mol. L) of pH 7.0-1) Preparation: mixing 0.68g KH2PO429.1mL of 0.1 mol. L was added-1Then diluted with ultrapure water to 100 mL). The prepared beta-CD @ AuNPs are shown in FIGS. 1(a) - (c).
CQDs are prepared by taking cetylpyridinium chloride (CPC) solution as a precursor and synthesizing the precursor by an ultrasonic one-step method. The method mainly comprises the following steps: to 100mL (15 mmol. L)-1) To the CPC solution (3) was added 9mL (2.0 mol. L)-1) After 30min of ultrasound (during which the solution changes from colorless to light yellow and finally to brownish yellow), the pH of the solution was adjusted to 7.0 with concentrated hydrochloric acid to terminate the reaction. Dialyzing with dialysis bag (Mw ≈ 3500) for 24h, freeze drying the solution to obtain Carbon Quantum Dots (CQDs) solid, dissolving the CQDs solid in water according to the concentration required by experiment, and storing at 4 deg.C. The CQDs thus obtained are shown in FIG. 1 (d).
As shown in FIG. 1, the prepared β -CD @ AuNPs and CQDs have red and brown-yellow colors, respectively, are spherical and have average particle sizes of about 25nm and 3nm, respectively.
2. Optical characteristics of the respective substances
As shown in FIG. 2(a), the fluorescence emission peak of CQDs is 528nm, the fluorescence excitation peak symmetrical to the fluorescence emission peak is 390nm, the blue curve is the ultraviolet-visible absorption spectrum of beta-CD @ AuNPs, the maximum absorption is at 528nm, and the maximum absorption is well coincident with the fluorescence emission peak of CQDs. The beta-CD @ AuNPs can efficiently quench the fluorescence of CQDs, and a fluorescence resonance energy transfer system can be constructed, wherein the CQDs are fluorescence energy donors, and the beta-CD @ AuNPs are fluorescence energy acceptors. The CQDs solution and the beta-CD @ AuNPs solution were bright yellow and wine red, respectively, in daylight (1 and 2 of the inset in FIG. 2), and the CQDs fluoresced strongly under 365nm UV light while the beta-CD @ AuNPs did not (5 and 6 of the inset in FIG. 2).
As shown in FIG. 2, the fluorescence emission peak of CQDs is obvious and the intensity is large; when the beta-CD @ AuNPs solution is added, fluorescence quenching occurs, the system solution is light red (3 of an insert in figure 2 (a)), and only weak fluorescence is shown under the irradiation of 365nm ultraviolet light (7 of an insert in figure 2 (a)); after the addition of cholesterol was continued, the fluorescence of CQDs was partially restored (FIG. 2(b)), and the color of the system solution was changed to dark pink (4 in the inset in FIG. 2 (a)), and the fluorescence was restored under 365nm ultraviolet light (8 in the inset in FIG. 2 (a)). Taken together, it is shown that β -CD @ AuNPs efficiently quench the fluorescence of CQDs, while cholesterol restores the fluorescence of CQDs, with a concomitant change in solution color.
3. Optimization of reaction conditions
As shown in FIG. 3(a), the fluorescence intensity of CQDs decreases with the increase in the volume of the added β -CD @ AuNPs, and the fluorescence intensity F of CQDs decreases when the volume of the added β -CD @ AuNPs is 0 to 2000. mu.L (FIG. 3b)0the/F is well linear with the volume of the added beta-CD @ AuNPs, and when the volume of the beta-CD @ AuNPs is increased continuously, the curve is bent upwards, which shows that the fluorescence quenching efficiency of CQDs is reduced. Therefore, 2mL of β -CD @ AuNPs were selected as the fluorescence quencher and the colorimetric indicator. Because both CQDs and β -CD @ AuNPs are prepared at around pH 7 in solution and are stable at around pH 7. As shown in FIG. 3(c), the fluorescence intensity of CQDs is quenched upon addition of β -CD @ AuNPs, the reaction is rapid, and the reaction time for fluorescence quenching is negligible. But cholesterol (60. mu. mol. L) was added-1) The fluorescence recovery time is not negligible, as shown in fig. 3(d), after the cholesterol is added, the fluorescence intensity of the CQDs is continuously increased along with the time extension, the fluorescence intensity tends to be stable at 40min, and the fluorescence recovery process is basically completed, so 40min is selected as the reaction time of the fluorescence recovery in the CQDs/β -CD @ AuNPs system.
4. Selective study of CQDs/beta-CD @ AuNPs on serum cholesterol
Performing fluorescence response measurement on main substances in serum, mainly comprising NaCl, KCl and MgCl2Glucose, uric acid, glycine, aspartic acid, glutamic acid, glutathione (reduced form), ascorbic acid and cholesterol (all at a concentration of 90. mu. mol. L)-1) As shown in FIG. 4(a), the recovery efficiency of cholesterol on CQDs/β -CD @ AuNPs is the most significant, reaching about 1.2. Overall CQDs/β -CD @ AuNPs are highly selective for cholesterol.
5. The specific detection method of this embodiment is as follows:
(1) 2mL of the prepared beta-CD @ AuNPs was added to 300. mu.L (0.4 mg. multidot.mL)-1) Adding appropriate amount of cholesterol stock solution (10 mmol. multidot.L with anhydrous ethanol as solvent) into CQDs-1) The preparation is 0, 10, 30, 50, 70, 90, 110, 130, 150, 170, 190, 210 mu mol & L-1The volume of the standard cholesterol solution was adjusted to 5mL with ultrapure water. The fluorescence excitation wavelength is fixed at 390nm, the fluorescence emission spectra of cholesterol standard solutions with different concentrations are respectively recorded, and the intensity of a fluorescence emission peak (Em 528nm) is used as a quantitative basis. Recovery of efficiency by fluorescence (F-F)0)/F0Linear fitting for different cholesterol concentrations (F)0F corresponds to the intensity of the fluorescence emission peak with different cholesterol concentrations added, for the intensity of the fluorescence emission peak without cholesterol added), the limit of detection of the method is determined. When the concentration of cholesterol is in the range of 10-210 mu mol.L-1When the fluorescence is recovered, the efficiency of fluorescence recovery (y ═ F-F)0)/F0) Shows a good linear relation (R) with the concentration (x) of cholesterol2＝0.996)，y＝0.0052x-0.0139。
(2) Determination of cholesterol content in animal serum
Fresh, clean pig blood was obtained from the market and stored in blue-capped reagent bottles overnight at room temperature. The light yellow supernatant was centrifuged every other day (4000rpm, 6min) to obtain relatively pure pig serum. The method of (1) was followed by adding 50. mu.L of pig serum and adding 0, 40, 80, 160. mu. mol. L of each-1The standard cholesterol solution is added to 5mL in constant volume and is added after 40minAnd (4) measuring fluorescence. All experiments were performed in triplicate at room temperature.
(3) And (3) substituting the fluorescence intensity values obtained before and after the step (2) into the linear working curve in the step (1) to obtain the corresponding cholesterol concentration.
The method analyzes and measures the cholesterol in the actual pig serum, and the result is shown in the table 1:
TABLE 1 fluorescence method based on CQDs/beta-CD @ AuNPs for porcine serum cholesterol concentration (. mu. mol. L)-1) Measurement of (n ═ 3)
In conclusion, the CQDs/beta-CD @ AuNPs fluorescent signal in the method of the embodiment is stable, has the advantages of good water solubility, low biotoxicity and the like compared with other fluorescent probes, utilizes the synergistic advantages of fluorescence resonance energy transfer and subject-object recognition, has wide linear range, high selectivity and low detection limit, and can effectively overcome the defects of methods such as chromatography, electrochemical method, colorimetric method, plasma absorption spectroscopy and the like. Cholesterol gave a linear working curve over different concentration ranges: y is 0.0052x-0.0139, linear range: 10-210. mu. mol. L-1. The experiment process is accompanied with the change of the solution color, and a method for detecting cholesterol by colorimetric-fluorescent double channels can be further developed.
The above description is only a preferred embodiment of the present invention, and therefore should not be taken as limiting the scope of the invention, which is defined by the appended claims.
Claims (3)
1. A method for detecting cholesterol in serum for non-diagnostic therapeutic purposes, comprising: the method comprises the following steps:
(1) mixing beta-CD @ AuNPs, CQDs and a proper amount of cholesterol stock solution prepared by taking absolute ethyl alcohol as a solvent to obtain mixed solutions containing cholesterol standard solutions with different concentrations; fixing the fluorescence excitation wavelength at 390nm, and recording the fluorescence excitation wavelengthFluorescence emission spectrum of the mixed solution of the cholesterol standard solution, the intensity of the fluorescence emission peak Em =528 nm as the quantitative basis, and the fluorescence recovery efficiency (F-F)0）/F0Linear fitting of different cholesterol concentrations, determination of detection limits, F0The intensity of the fluorescence emission peak Em =528 nm when cholesterol is not added, and the intensity of the fluorescence emission peak Em =528 nm when F corresponds to the concentration of different cholesterol standard solutions; when the concentration of cholesterol is 10-210 mu mol.L-1Fluorescence recovery efficiency (F-F)0）/F0Shows good linear relation with the concentration of cholesterol, and obtains a linear working curve y =0.0052x-0.0139, R2=0.996，y=（F-F0）/F0X is cholesterol concentration; the beta-CD @ AuNPs are gold chloride acid (HAuCl)4) The CQDs are synthesized by a one-step ultrasonic method by taking cetylpyridinium chloride (CPC) solution as a precursor;
(2) preserving fresh blood at room temperature overnight, and centrifuging light yellow supernatant every other day to obtain serum; adding 0-160 mu mol.L into the serum-1Performing fluorescence measurement according to the parameters of the step (1), and repeating the measurement for at least three times to obtain the intensity of a corresponding fluorescence emission peak Em =528 nm;
(3) substituting the intensity of the fluorescence emission peak Em =528 nm obtained in the step (3) into the linear working curve to obtain the concentration of cholesterol in serum;
the preparation method of the beta-CD @ AuNPs comprises the following steps: 35mL of ultrapure water and 5mL of 0.1 mol. L were added in this order to the reaction vessel-1And 1mL of 0.01mol. L PBS buffer solution having a pH of 7.0-1HAuCl of4Solution and 10mL of 0.01mol. L-1Stirring the beta-CD aqueous solution uniformly, transferring the solution into an oil bath kettle, stirring and refluxing for 60min at 100 ℃ with strong force, changing the color of the solution from light yellow to light red, finally changing the solution into wine red, naturally cooling the solution, filtering the solution by a 0.45 mu m filter membrane, and storing the solution at 4 ℃;
the preparation method of the CQDs comprises the following steps: to 100mL of 15 mmol. L-1CPC solution of9mL of 2.0 mol. L was added to the solution-1After the ultrasonic treatment is carried out for 30min, the pH value of the solution is adjusted to 7.0 by concentrated hydrochloric acid, the reaction is terminated, and the CQDs solid is obtained by freeze drying after being dialyzed for 24h by a dialysis bag, and is dissolved in water again according to the concentration required by the experiment and stored at 4 ℃; the solution changed color from colorless to light yellow and finally to brown-yellow during sonication.
2. The detection method according to claim 1, characterized in that: the average particle size of the beta-CD @ AuNPs is 24-26 nm.
3. The detection method according to claim 1, characterized in that: the CQDs have an average particle size of 2.8-3.2 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811304853.9A CN109520979B (en) | 2018-11-02 | 2018-11-02 | A kind of detection method of cholesterol in serum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811304853.9A CN109520979B (en) | 2018-11-02 | 2018-11-02 | A kind of detection method of cholesterol in serum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109520979A CN109520979A (en) | 2019-03-26 |
| CN109520979B true CN109520979B (en) | 2021-07-20 |
Family
ID=65774294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811304853.9A Active CN109520979B (en) | 2018-11-02 | 2018-11-02 | A kind of detection method of cholesterol in serum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109520979B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110554205B (en) * | 2019-09-17 | 2022-08-12 | 浙江大学山东工业技术研究院 | Method for preparing high-density lipoprotein cholesterol assay test paper |
| CN111122528B (en) * | 2019-12-19 | 2022-09-23 | 扬州大学 | SiO 2 Sol-gel encapsulated CsPbBr 3 Method for detecting cholesterol by quantum dots |
| CN113801650B (en) * | 2021-08-26 | 2023-07-14 | 桂林电子科技大学 | A kind of mercapto β-cyclodextrin-gold nanocluster and its preparation method and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101180542A (en) * | 2004-12-11 | 2008-05-14 | 科学技术设备委员会 | Cholesterol determination |
| CN104198740A (en) * | 2014-07-29 | 2014-12-10 | 中山大学 | Nanometer biosensor for synchronously detecting glucose and cholesterol |
| CN104597019A (en) * | 2015-01-26 | 2015-05-06 | 郑州大学 | In-situ composite system based on carbon quantum dot/manganese dioxide nanometer sheet layer and using method for detecting content of glutathione |
| CN105417492A (en) * | 2015-11-04 | 2016-03-23 | 安徽师范大学 | Method for preparing beta-cyclodextrin-gold nano-particles and method for detecting cholesterol |
| CN107478621A (en) * | 2017-06-26 | 2017-12-15 | 南京医科大学 | Metabolizable generation H in serum is detected by ratio fluorescent probe quantitative2O2Biomolecule method |
| CN105675559B (en) * | 2016-01-14 | 2018-01-30 | 中国科学院理化技术研究所 | Method for detecting dopamine by using carbon dots as fluorescent probes |
-
2018
- 2018-11-02 CN CN201811304853.9A patent/CN109520979B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101180542A (en) * | 2004-12-11 | 2008-05-14 | 科学技术设备委员会 | Cholesterol determination |
| CN104198740A (en) * | 2014-07-29 | 2014-12-10 | 中山大学 | Nanometer biosensor for synchronously detecting glucose and cholesterol |
| CN104597019A (en) * | 2015-01-26 | 2015-05-06 | 郑州大学 | In-situ composite system based on carbon quantum dot/manganese dioxide nanometer sheet layer and using method for detecting content of glutathione |
| CN105417492A (en) * | 2015-11-04 | 2016-03-23 | 安徽师范大学 | Method for preparing beta-cyclodextrin-gold nano-particles and method for detecting cholesterol |
| CN105675559B (en) * | 2016-01-14 | 2018-01-30 | 中国科学院理化技术研究所 | Method for detecting dopamine by using carbon dots as fluorescent probes |
| CN107478621A (en) * | 2017-06-26 | 2017-12-15 | 南京医科大学 | Metabolizable generation H in serum is detected by ratio fluorescent probe quantitative2O2Biomolecule method |
Non-Patent Citations (2)
| Title |
|---|
| Surfactant-Derived Amphiphilic Carbon Dots with Tunable Photoluminescence;Ondřej Kozák et al.;《The Journal of Physical Chemistry》;20131101;第117卷;第24991页右栏最后1段-第24992页左栏第2.1节 * |
| Yellow-Emissive Carbon Dot-Based Optical Sensing Platforms: Cell Imaging and Analytical Applications for Biocatalytic Reactions;Li Hongxia et al.;《Applied Materials & Interfaces》;20180214;第10卷;第7734-7744页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109520979A (en) | 2019-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alshatteri et al. | Smartphone-based fluorescence detection of bilirubin using yellow emissive carbon dots | |
| CN109520979B (en) | A kind of detection method of cholesterol in serum | |
| CN107573933B (en) | A carbon quantum dot-copper ion fluorescent probe and its preparation method and application | |
| Nevado et al. | Spectrofluorimetric study of the β-cyclodextrin: vitamin K3 complex and determination of vitamin K3 | |
| WO2003097863A1 (en) | Method and reagent system having an inactivated enzyme | |
| CN112964683B (en) | Preparation and application of folic acid-modified nitrogen-doped graphene quantum dots/silver nano-fluorescent probes | |
| Ma et al. | A “switch-on” fluorescence assay based on silicon quantum dots for determination of ascorbic acid | |
| JP2011158425A (en) | Visual fluorescence analysis device, and analysis method for trace heavy metal using the same | |
| CN105772742B (en) | A kind of preparation method and application of fluorescence gold nano cluster | |
| CN109632731B (en) | Single-excitation double-emission carbon-based biomass quantum dot and preparation method and application thereof | |
| CN113528134A (en) | Nano fluorescent probe, its preparation method and application | |
| JP6475671B2 (en) | Protein detection | |
| Alhazzani et al. | A dual emissive silver-riboflavin complex and nitrogen-doped carbon dot nanoprobe for ratiometric detection of glutathione | |
| CN110407845A (en) | A kind of naphthyl derivative molecule, its preparation method and the detection method of dopamine | |
| CN107936035A (en) | A kind of cysteine-modifying graphene quantum dot GQCY and preparation method are with preparing the application on dopamine luciferase assay reagent | |
| CN105044060A (en) | Preparation and application of red fluorescent silver nanocluster | |
| Dehghan et al. | A novel ultrasensitive and non-enzymatic “turn-on-off” fluorescence nanosensor for direct determination of glucose in the serum: As an alternative approach to the other optical and electrochemical methods | |
| CN111999275B (en) | Method for rapidly and quantitatively measuring pH value and/or uric acid | |
| Mori et al. | Sensitive spectrophotometric determination of human serum albumin (HSA) with (2-(5-bromo-2-pyridylazo)-5-(N-phenyl-N-sulfopropylamino) phenol)(5-Br. PAPS)-cobalt (II)) complex | |
| CN110018146B (en) | A method for detecting palladium ions based on fluorescent carbon quantum dots | |
| Li et al. | Gold nanoclusters anchored manganese dioxide nanocomposites with high structural stability for sensitive detection of methyl parathion | |
| JP4082505B2 (en) | Alcohol analysis method | |
| CN106928263A (en) | A kind of preparation and application of the fluorescence probe for quick detection hydrogen peroxide | |
| CN109612973B (en) | Method for detecting cholesterol and concentration thereof through fluorescent gold nanocluster probe and method for detecting cholesterol oxidase and concentration thereof | |
| CN105954248A (en) | Arsenite detection method based on DNA biological quantum dot fluorescence enhancement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |